G
MP-140 (P-selectin) is a member of a family of cell adhesion receptors termed selectins, which mediate one or more aspects of leukocyte adhesion (1, 2) . Selectins share a common structural theme: an NH2-terminal calcium-dependent lectin domain, an epidermal growth factor motif, a variable number of repeats of a sequence found in complement regulatory proteins, a transmembrane domain, and a short cytoplasmic tail (3) . For GMP-140, each of these domains is encoded by separate exons (4) . Cloning data from an endothelial cell library predicts the existence of three separate forms of GMP-140, two of which differ in the number of complement regulatory protein repeats, while a third form lacks a transmembrane domain, and hence predicts a soluble form of GMP-140 (3) . In support of this, human platelets have been found to contain approximately equal amounts of mRNA encoding for GMP-140 with and without the transmembrane domain (4) .
Surface-expressed membrane GMP-140 mediates the binding of activated platelets to myeloid cells and the transient adhesion of neutrophils to thrombin-stimulated endothelial cells (2, 5) . In contrast, we have found that GMP-140 can also serve an antiinflammatory function in that exposure of TNFo~-activated neutrophils to fluid-phase platelet membrane GMP-140 inhibits their CD18-dependent adhesion to resting endothelium (6) and superoxide production (7) . In the present study, we demonstrate that soluble GMP-140 circulates in normal plasma in a soluble and potentially functional form and is secreted from activated platelets.
Materials and Methods
Monoclonal and Polyclonal Anti-GMP-140 Antibodies, The murine mAbs AK4 and AK6, at~nity-purified rabbit polyclonal anti-GMP-140 antibody, and preparation of nonimmune rabbit IgG have been previously described (8, 9) . LeoA1 is a routine mAb directed against the 65-kD PTA1 antigen (10) .
Secretion of GMP-14O from Thrombin-stimulated Platelets. Washed platelets were isolated from anticoagulated venous blood either in the presence or absence of PGEt (3 /~M, final concentration). Platelets (109/ml) isolated in the absence of PGE1 were subsequently activated by the addition of o~ thrombin (1 U/ml, final concentration). Resting (PGE 0 and activated ((x thrombin) platelets were pelleted by centrifugation at 1,000 g. The platelet supernatants were recentrifuged at 1,500 g to remove residual platelets, and divided in two, with one sample being further centrifuged at 100,000 g for 3 h. Samples were analyzed under nonreducing conditions on a 5-20% gradient SDS-polyacrylamide gel, transferred to nitrocellulose, and immunoblotted for GMP-140 using affinity-purified rabbit anti-GMP-140 antibody (1/~g/ml) or rabbit nonimmune IgG (1 /~g/ml) as control.
Detection and Quantitation of Plasma GMP-140 by ELISA. Venous blood was collected from normal laboratory volunteers who had been medication free for 10 d before study. Blood (nine parts) was collected using a 19-gange Terumo-winged infusion set directly into 3.2% trisodium citrate (one part) as anticoagulant and processed immediately. Alternatively, in some experiments in order to mimic normal hospital collection procedures, venous blood collected with a 21-gauge needle was added to a 5-ml buffered sodium citrate vacutainer (Becton Dickinson & Co., Mountain View, CA) and allowed to sit 2 h before processing. Platelet-poor plasma was prepared by centrifugation at 1,500 g for 20 min, then microfuged at 10,000 g for 5 min, and finally ultracentrifuged at 100,000 g for 3 h. GMP-140-depleted plasma was prepared by batch absorption overnight of ultracentrifuged plasma with AK4-Affigel-10 followed by centrifugation at 1,500 g for 20 min. Surface-expressed GMP-140 on platelets was quantitated as previously described (8) .
Plasma GMP-140 levels were quantitated using a sandwich ELISA that employed immobilized affinity-purified rabbit anti-GMP-140 antibody and detection with the murine anti-GMP-140 mAb AK6. Briefly, 200/~1 of affinity-purified rabbit anti-GMP-140 antibody (0.4/~g/ml) in 0.1 M sodium bicarbonate buffer, pH 8.3, was added to each well of an EIA microtiter plate (Linbro/Titertek, McLean, VA) and incubated overnight at 4~ After three washes with ELISA buffer (0.12 M NaC1, 0.02 M imidazole, 0.005 M citric acid, 0.1% [wt/vol] BSA, pH 7.3), each well was blocked with 5% (wt/vol) BSA in ELISA buffer for 1 h at room temperature. After washing three times, 20 #1 of each plasma was added to each of three wells containing 180 txl of ELISA buffer. For each experiment, a standard curve was generated using purified platelet membrane GMP-140 (0-1.6/~g/ml, final concentrations). For the standard curve, 20/~1 of serially diluted platelet membrane GMP-140 was added in triplicate to 160/~1 of ELISA buffer and 20 #1 of GMP-140-depleted plasma. After 1 h, the plates were washed four times, and 200/~1 of AK6 IgG in ELISA buffer (2.5/~g/ml, final) was then added. After 1 h, the plate was rewashed five times and 200/zl of a i in 1,000 dilution of horseradish peroxidase-conjugated rabbit anti-mouse IgG was added for 1 h. The plate was washed five times and color developed using 200/~l/well of 0.42 M 3,3',5, 5'-tetramethylbenzidine dihydrochloride in 0.1 M acetate buffer, pH 6, containing 1.3 mM hydrogen peroxide. The reaction was stopped after 10 min by the addition of 50/~1 of 2 M sulphuric acid. Absorbance was then read on an automated reader (EL312; Biokinetics, Winooski, VT) at 450 vs. 490 nm.
Purification of Plasma GMP.140. Fresh platelet-poor plasma obtained on the day of collection from the Red Cross Blood Bank (Parramatta, Sydney) was centrifuged at 10,000 g for 1.5 h in order to remove residual platelets. Buffers used for the purification of plasma GMP-140 included 0.1% (wt/vol) Triton X-100, due to the marked propensity of plasma GMP-140 to irreversibly absorb to surfaces during its isolation. The plasma was loaded onto an AK6-Affigel-10 column that had been equilibrated with 0.01 M Tris, 0.15 M NaC1, 0.1% (wt/vol) Triton X-100, and 0.02% (wt/vol) sodium azide, pH 7.4 (buffer A). After exhaustive washing with buffer A and buffer A made 1 M in NaC1 and 1 mM in EDTA, the column was eluted with 0.1 M glycine, 0.1% (wt/vol) Triton X-100, pH 2.4, and immediately neutralized by the addition of onefifth volume of I M Tris, pH 8.0. GMP-140-rich fractions as evaluated by SDS-PAGE were pooled and dialyzed overnight against buffer A. BSA (10 mg/ml) was then added to help prevent nonspecific absorption of contaminating proteins in the next immunoaffinity step. The crude GMP-140 was then loaded onto sequential LeoA1-Affigel-10 and AK4-Affigel-10 columns. After thorough washing of the AK4 column, bound GMP-140 was eluted, neutralized, and then dialyzed against buffer A as described above. GMP-140-rich fractions were then loaded onto a column of heparin-Sepharose Cb 6B. Purified GMP-140 was eluted using a 50-ml linear 0.15-1.0 M NaC1 gradient in buffer A. Platelet membrane GMP-140 was purified from human platelets as previously described in detail (8). Triton-X-100 was removed from purified platelet membrane and plasma GMP-140 using Extractigel-D resin as previously described (9) . Platelet membrane and plasma GMP-140 were 12SI-labeled as described (9) .
Interaction of Plasraa GMP-140 with Neutrophils. Neutrophil isolation, binding of 12SI-labeled GMP-140 to neutrophils, and adhesion of neutrophils to GMP-140-coated plastic were all performed as previously described in detail (6) (7) (8) .
Analytical Methods. NH2-terminal peptide sequence analysis, analytical gel filtration, SDS-PAGE, gel staining, and Western blot analysis were performed as previously described in detail (9, 11, 12) .
Results

Secretion of GMP-140 from Platelets.
Since cDNA and platdet mRNA analysis both predict a soluble form of GMP-140 with a ddeted transmembrane domain (3, 4), we initially examined whether GMP-140 was secreted from phtdets on activation. GMP-140 could be detected by Western blot analysis in the supernatant of thrombin-stimulated platdets but not control platelets (Fig. 1 B, lane 2 vs. Fig. 1 A, lane  2) , even after the platelet supernatant had been centrifuged at 100,000 g for 3 h (Fig. 1 B, lane 3) . The majority of the platdet GMP-140, however, remained platdet-associated after thrombin stimulation (Fig. 1 B, lane I vs. Fig. 1 A, lane  I) . Since platdet microparticles that contain GMP-140 would sediment at 100,000 g (13) , this experiment suggests that GMP-140 can exist in soluble form.
Detection of GMP-140 in Plasma.
A sensitive ELISA for the measurement of GMP-140 levels in ultracentrifuged plasma was developed. Addition of known amounts of purified phtelet membrane GMP-140 to either GMP-140-depleted plasma or normal plasma indicated that the determined level of GMP-140 in plasma was strictly additive at 0-1.0 t~g/ml. Plasma from 10 normal male and 10 normal female donors (age range, 20-40 yr) gave GMP-140 levels of 0.251 __ 0.043 and 0.175 _+ 0.063 t~g/ml (~ --SD), respectively (p < 0.01, unpaired student's t test). Western blot analysis of serially diluted plasma and known amounts of platelet membrane GMP-140 were also consistent with a plasma level of GMIX140 of'~0.2/~g/ml (data not shown). Under our standard conditions for venous Figure 1 . Secretion of GMP-140 from platdets. Control (,4) and thrombin-activated platelets (B) were separated on a 5-20% exponential SDS-polyacrylamide gel, transferred to nitrocdhlose, and immunoblotted with a/finitypurified rabbit anti-GMP-140 antibody. Lane 1, phtdet pellet; lane 2, platelet supernatant; lane 3, platelet supernatant centrifuged at 100,000 g for 3 h. Molecular weight markers in decreasing order are myosin (200,000), B-galactosidase (130,000), phosphorylase B (94,000), BSA (68,000), and OVA (43,000). blood sampling, the platdets in platelet-rich plasma had <100 copies of surface-expressed GMP-140 compared with -10,000 copies on the surface of fully activated platelets (1), indicating that the plasma GMP-140 did not arise due to platelet activation during sample collection. In addition, the plasma GMP-140 level was insensitive to different collection procedures (Materials and Methods), indicating that the assay could be applied to routinely collected, hospital-citrated plasma samples. Finally, the plasma GMP-140 level in plasma centrifuged at 10,000 g for 5 min vs. plasma centrifuged at 100,000 g for 3 h was not significantly different, indicating that plasma GMP-140 could not be accounted for as microparticle contamination. In this regard, it can be calculated from the data of George et al. (13) that microparticle-associated GMP-140 Purification of Plasma GMP-140. GMP-140 was purified to homogeneity from pooled normal human plasma (see Materials and Methods) with an overall yield of "~100/~g from 6 liters of starting plasma. Relative to platelet membrane GMP-140, the purified protein had similar binding characteristics to heparin, a similar molecular mass on SDS-PAGE under nonreducing and reducing conditions (Fig. 2) , crossreacted with monoclonal and polyclonal anti-GMP-140 antibodies (data not shown), and had an identical NH2-terminal peptide sequence, WTYHYSTKAYSWXFSR (3). Plasma GMP-140, however, differed from platelet membrane GMP-140 in that its reduced molecular mass on SDS-polyacrylamide gels was "~3 kD lower (Fig. 2) , and in that on analytical gel filtration under detergent-free conditions, it did not elute as tetramers (9) but remained monomeric. Both these results are consistent with the plasma form of GMP-140 lacking a transmembrane domain. Given that platelets contain mRNA encoding soluble GMP-140 (4) and that soluble GMP-140 is secreted from activated platelets (this study), it is probable that plasma GMP-140 represents the alternatively spliced, soluble form of GMP-140 lacking the transmembrane sequence encoded by exon 14 (4). It remains possible, however, that plasma GMP-140 is proteolytically derived from the membrane-bound form of GMP-140.
Plasma GMP-140 Is Functional. Since we have previously established that fluid-phase GMP-140 regulates various aspects of neutrophil function, it was important to establish whether plasma GMP-140 retained the capacity to interact with neutrophils. Plasma GMP-140 bound specifically to neutrophils. As for binding of platelet membrane GMP-140 to neutrophils (9, 14) , this binding was divalent-cation dependent, as it was inhibited by excess EDTA. In addition, binding was completely inhibited by affinity-purified rabbit anti-GMP-140 Fab fragments, inhibited by *50% by the anti-GMP-140 mAb AK4, but not by AK6 (9) . Excess plasma GMP-140 completely inhibited the binding of radioiodinated platelet membrane GMP-140 to neutrophils (and vice versa) suggesting, as expected, that both the platelet membrane and plasma forms of GMP-140 bind to the same receptor (data not shown). Finally, neutrophils bound equally well to platelet membrane and plasma GMP-140 immobilized on plastic (Fig. 3) .
Discussion
Current evidence suggests that GMP-140 plays a fundamental role in both limiting and mediating the inflammatory responses of neutrophils (2, 6, 7) . In the present study, we demonstrate that GMpo140 circulates in a soluble and potentially functional form in plasma and is secreted in soluble form from activated platelets. In normals, the plasma concentration of GMP-140 was found to be •0.15-0.30 #g/ml. Based on the measured binding characteristics of fluid-phase platelet membrane GMP-140 to neutrophils (9) , this would correspond to 20-40% saturation of neutrophil GMP-140 receptors, potentially allowing both an antiinflammatory action (6, 7) as well as the focal adhesion of neutrophils to GMP-140 expressed on activated endothelium (2) .
GMP-140 has only been localized to the cr granules of platelets (and megakaryocytes) and the Weibel-Palade bodies of endothelium (1) , and is surface expressed on both cell types on cellular activation. Since mRNA encoding the soluble form exists in both endothelium (3) and platelets (4), plasma GMP-140 must derive from either one or both of these sources. One would therefore predict that the plasma level of GMP-140 could provide a useful marker of either platelet activation and/or vascular endothelial perturbation in thrombotic and inflammatory diseases. This topic is under current investigation.
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